NCT03562975 - Upper Extremity Function in Multiple Sclerosis Patients With Advanced Disability Treated With Ocrevus | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 23, 2018

Primary Completion Date

January 11, 2023

Study Completion Date

January 11, 2023

Conditions

Multiple SclerosisPathologic ProcessesDemyelinating DiseasesNervous System DiseasesAutoimmune DiseasesImmune System DiseasesPrimary Progressive Multiple SclerosisRelapsing Remitting Multiple Sclerosis

Interventions

DRUG

Ocrelizumab

Ocrelizumab is a humanized anti-CD20 monoclonal antibody. It targets CD20 marker on B lymphocytes and hence is an immunosuppressive drug candidate. Ocrelizumab binds to an epitope that overlaps with the epitope to which rituximab binds

Trial Locations (1)

33612

Carol and Frank Morsani Center for Advanced Healthcare, Tampa